Ribo Receives Granted Patents for Phase 2 HBV siRNA Asset RBD1016 in United States and Europe

Ribocure Pharmaceuticals/Suzhou Ribo Life Science Co. Ltd. (“Ribo”) announce Notice of Allowance issued respectively by US Patent Office and European Patent Office for patent applications covering the anti-hepatitis B siRNA drug RBD1016.

With the approved patents in US and Europe, and with the previous authorizations in six major countries/regions, including China and Japan, Ribo’s strategy to support the use of RBD1016 globally for treatment of Chronic Hepatitis B infection (CHB) continues to execute. Ribo holds already a strong patent portfolio for both its individual programs and its proprietary GalNAc-siRNA liver targeting platform,
RIBO-GalSTARTM.

About RBD1016
Hepatitis B is an infectious disease caused by the hepatitis B virus. Nearly 300 million people are infected worldwide with an increased risk of suffering from liver cirrhosis and liver cancer. There is a huge unmet clinical need for potent and safe treatment options for this group of patients.

The goal for treating CHB is to achieve a clinical cure (functional cure), where HBsAg (hepatitis B surface antigen) remains negative with or without the presence of anti-HBs (antibodies to hepatitis B surface antigen, HBsAb), HBV DNA is undetectable, liver biochemistry remains normal, and liver histopathology improves after stop of treatment. RBD1016 is a GalNAc-siRNA drug independently developed by Ribo based on its proprietary GalNAc-siRNA platform, targeting the X gene of hepatitis B virus. It inhibits all four HBV transcripts through the RNA interference mechanism, and can simultaneously inhibit HBV DNA replication, reduce cccDNA and integrate DNA derived HBsAg and other antigens. RBD1016 demonstrates well-tolerated safety profile in Phase I study including both healthy subjects and patients with CHB infection. RBD1016 shows a highly efficient long-acting effect of reducing the HBsAg in patients. Ribo regards RBD1016 as the best-in-class siRNA for targeting of HBV and has currently a global multicenter Phase II clinical trial in progress.

Share on social media

Privacy Policy (Integritetspolicy)
Your privacy is important to us. Ribocure Pharmaceuticals AB respects your privacy regarding all data we may collect from you on our website, www.ribocure.com.
 
We collect data/information to make contact and establish and maintain a relationship. We collect this information in a fair and legal way with your awareness and consent, as stipulated by GDPR (General Data Protection Regulation). We also let you know why we collect it and how it will be used.
 
The data that is stored are the fields that each submission form contains. We save the data for as long as is necessary with regard to the purposes of the processing. We always base the collection of personal data on consent.
 
You have the right to request information about what personal data we have stored about you. To do this, contact the Data Protection Officer (DPO). You also have the right to request correction or deletion of your personal data at any time.
 
Your continued use of our website will be deemed as acceptance of our privacy and personal information practices. If you have any questions about how we handle user data and personal information, please contact us.
 
Contact information to the Data Protection Officer (DPO):
 
Data Protection Officer
Ribocure Pharmaceuticals AB
Vetenskapens gränd 11
431 53 Mölndal
Sweden
 
E-mail: dpo@ribocure.com